> top > docs > PubMed:10037799 > annotations

PubMed:10037799 JSONTXT

Annnotations TAB JSON ListView MergeView

bionlp-st-gro-2013-training

Id Subject Object Predicate Lexical cue
T1 0-6 Protein denotes LYVE-1
T2 31-35 Protein denotes CD44
T3 36-48 Protein denotes glycoprotein
T4 55-60 Tissue denotes lymph
T5 70-78 Protein denotes receptor
T6 83-93 Chemical denotes hyaluronan
T7 150-152 Chemical denotes HA
T9 182-186 Tissue denotes skin
T10 191-210 Tissue denotes mesenchymal tissues
T14 373-379 Tissue denotes tissue
T15 388-390 Chemical denotes HA
T17 429-446 Tissue denotes lymphatic vessels
T18 454-465 Tissue denotes lymph nodes
T20 543-548 Tissue denotes liver
T21 588-590 Chemical denotes HA
T23 599-608 MolecularEntity denotes molecules
T26 691-697 Protein denotes LYVE-1
T27 735-743 Protein denotes receptor
T28 748-750 Chemical denotes HA
T29 758-775 Tissue denotes lymph vessel wall
T30 789-799 AminoAcid denotes amino acid
T31 812-818 Protein denotes LYVE-1
T41 1027-1039 Protein denotes Link protein
T42 1058-1062 Protein denotes CD44
T43 1068-1083 Protein denotes LYVE-1 molecule
T45 1119-1121 Chemical denotes HA
T46 1139-1143 Protein denotes CD44
T47 1149-1164 Protein denotes LYVE-1 molecule
T48 1182-1184 Chemical denotes HA
T49 1212-1229 Tissue denotes lymph vessel wall
T50 1260-1273 Tissue denotes blood vessels
T51 1282-1288 Protein denotes LYVE-1
T52 1302-1307 Tissue denotes lymph
T53 1317-1319 Chemical denotes HA
T54 1320-1328 Protein denotes receptor
T55 1387-1400 Tissue denotes lymph vessels
T56 800-808 Sequence denotes sequence
T32 842-878 Peptide denotes type I integral membrane polypeptide
T33 898-914 Protein denotes CD44 HA receptor
T34 934-954 ProteinDomain denotes extracellular domain
T35 975-1019 ProteinDomain denotes Link module the prototypic HA binding domain
E1 232-246 CellularProcess denotes cell migration
E2 287-310 DevelopmentalProcess denotes embryonic morphogenesis
E3 394-403 Transport denotes mobilized
E4 478-486 MetabolicPathway denotes degraded
E5 591-598 Binding denotes binding
E6 615-622 RegulatoryProcess denotes control
E7 628-635 Pathway denotes pathway
E9 1084-1089 BindingToProtein denotes binds
E10 331-349 OrganismalProcess denotes tissue homeostasis
R19 T45 E9 hasPatient HA,binds
R20 T43 E9 hasPatient LYVE-1 molecule,binds
R1 T7 T9 locatedIn HA,skin
R2 T7 T10 locatedIn HA,mesenchymal tissues
R3 E4 T20 locatedIn degraded,liver
R5 T31 T30 hasPart LYVE-1,amino acid
R7 T51 T55 locatedIn LYVE-1,lymph vessels
R8 T5 T4 locatedIn receptor,lymph
R9 T27 T29 locatedIn receptor,lymph vessel wall
R4 T34 T35 hasPart extracellular domain,Link module the prototypic HA binding domain
R6 T48 T49 locatedIn HA,lymph vessel wall
R10 T47 T49 locatedIn LYVE-1 molecule,lymph vessel wall
R11 T54 T52 locatedIn receptor,lymph
R13 T15 E3 hasPatient HA,mobilized
R14 T15 E4 hasPatient HA,degraded
R15 T23 E5 hasAgent molecules,binding
R16 T21 E5 hasPatient HA,binding
R17 T23 E6 hasAgent molecules,control
R18 E7 E6 hasPatient pathway,control

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-94 Sentence denotes LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan.
T2 95-311 Sentence denotes The extracellular matrix glycosaminoglycan hyaluronan (HA) is an abundant component of skin and mesenchymal tissues where it facilitates cell migration during wound healing, inflammation, and embryonic morphogenesis.
T3 312-549 Sentence denotes Both during normal tissue homeostasis and particularly after tissue injury, HA is mobilized from these sites through lymphatic vessels to the lymph nodes where it is degraded before entering the circulation for rapid uptake by the liver.
T4 550-648 Sentence denotes Currently, however, the identities of HA binding molecules which control this pathway are unknown.
T5 649-776 Sentence denotes Here we describe the first such molecule, LYVE-1, which we have identified as a major receptor for HA on the lymph vessel wall.
T6 777-1052 Sentence denotes The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily.
T7 1053-1122 Sentence denotes Like CD44, the LYVE-1 molecule binds both soluble and immobilized HA.
T8 1123-1274 Sentence denotes However, unlike CD44, the LYVE-1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels.
T9 1275-1412 Sentence denotes Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.
T1 0-94 Sentence denotes LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan.
T2 95-311 Sentence denotes The extracellular matrix glycosaminoglycan hyaluronan (HA) is an abundant component of skin and mesenchymal tissues where it facilitates cell migration during wound healing, inflammation, and embryonic morphogenesis.
T3 312-549 Sentence denotes Both during normal tissue homeostasis and particularly after tissue injury, HA is mobilized from these sites through lymphatic vessels to the lymph nodes where it is degraded before entering the circulation for rapid uptake by the liver.
T4 550-648 Sentence denotes Currently, however, the identities of HA binding molecules which control this pathway are unknown.
T5 649-776 Sentence denotes Here we describe the first such molecule, LYVE-1, which we have identified as a major receptor for HA on the lymph vessel wall.
T6 777-1052 Sentence denotes The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily.
T7 1053-1122 Sentence denotes Like CD44, the LYVE-1 molecule binds both soluble and immobilized HA.
T8 1123-1274 Sentence denotes However, unlike CD44, the LYVE-1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels.
T9 1275-1412 Sentence denotes Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.

PMID_GLOBAL

Id Subject Object Predicate Lexical cue mondo_id
T1 182-186 DiseaseOrPhenotypicFeature denotes skin 0002531
T2 254-259 DiseaseOrPhenotypicFeature denotes wound 0021178
T3 380-386 DiseaseOrPhenotypicFeature denotes injury 0021178
T4 1200-1204 DiseaseOrPhenotypicFeature denotes face 0010953